Heart Failure
RSSArticles
-
The Hemodynamic Effects of an SGLT2 Inhibitor in Heart Failure with Preserved Ejection Fraction
The authors of a small, placebo-controlled study of 24 weeks of dapagliflozin therapy in patients with heart failure with preserved ejection fraction reported reductions in pulmonary capillary wedge pressure, which may explain the reductions in heart failure hospitalizations or cardiovascular death in larger randomized outcome trials.
-
Diltiazem Found to Be Better than Metoprolol in Heart Rate Reduction for Atrial Fibrillation in Heart Failure
In patients with atrial fibrillation and heart failure, intravenous diltiazem results in greater heart rate reduction than metoprolol with a similar safety profile, but further research is needed in this patient population.
-
More Daily Steps Lowers Cardiovascular Disease Risk Among Older Adults
Researchers reported that for every additional 500 steps per day, the risk for heart disease, heart failure, and stroke declined by 14% among adults age 70 years and older.
-
Researchers Find Little Difference in Efficacy Between Top Heart Failure Treatments
In a head-to-head comparison of furosemide and torsemide, one diuretic was not significantly more efficacious than the other in improving heart failure survival rates.
-
Is It Better to Up-Titrate Medications Faster in Acute Heart Failure Patients?
Early intensive up-titration of guideline-recommended therapy in patients admitted for heart failure reduced 180-day readmission and all-cause mortality at the cost of more adverse events (but not serious or fatal ones).
-
Importance of Medication Adherence in Ischemic Heart Disease
The results of a subanalysis of the ISCHEMIA trial indicated about one-quarter of patients in both conservative and invasive strategy groups were nonadherent to recommended medical therapy at baseline. Nonadherence was associated with worse health status in both groups at baseline and after one year.
-
Top Heart Medication Could Help Alcohol Use Disorder Patients
Spironolactone is known to block mineralocorticoid receptors, an action believed to reduce alcohol cravings.
-
Predicting the Tolerability of Sacubitril/Valsartan in Advanced Heart Failure
An analysis of the sacubitril/valsartan run-in period for chronic, advanced heart failure patients showed 18% could not tolerate the lowest dose, usually because of hypotension or renal dysfunction. Investigators identified six predictors of non-tolerance, which may help clinicians choose the best candidates.
-
Are SGLT2 Inhibitors Effective for HFpEF Patients Without Diabetes?
After comparing empagliflozin to placebo for patients with heart failure and preserved left ventricular ejection fraction, researchers found no differences in the significant reduction of the primary outcome of cardiovascular death or heart failure hospitalization over 36 months based on whether patients were diabetic.
-
Predicting the Tolerability of Sacubitril/Valsartan in Advanced Heart Failure
An analysis of the sacubitril/valsartan run-in period for chronic, advanced heart failure patients showed 18% could not tolerate the lowest dose, usually because of hypotension or renal dysfunction. Investigators identified six predictors of non-tolerance, which may help clinicians choose the best candidates.